TPIDB > Principal Investigator
Principal Investigator
National Taiwan University Hospital
(在職)
Division of General Internal Medicine
Division of Hematology & Oncology
Division of General Surgery
National Taiwan University Cancer Center
(在職)
Division of General Internal Medicine
Division of Hematology & Oncology
更新時間：2025-03-10
鄭安理Cheng, Ann-Lii
- Principal Investigator
- Clinical Trial Experience (year) 23 years 9 個月
Publication
48Publications
31
Yang SH, Guo JC, Hsu C, Kuo SH, Tien YW, Cheng AL, Yeh KH. Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients. J Formos Med Assoc. 2020 Jan;119(1 Pt 1):97-105. doi: 10.1016/j.jfma.2019.01.015. Epub 2019 Mar 7. PMID: 30852003.
32
Evans TRJ, Kudo M, Finn RS, Han KH, Cheng AL, Ikeda M, Kraljevic S, Ren M, Dutcus CE, Piscaglia F, Sung MW. Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. Br J Cancer. 2019 Jul;121(3):218-221. doi: 10.1038/s41416-019-0506-6. Epub 2019 Jun 28. Erratum in: Br J Cancer. 2019 Jul 30;: PMID: 31249394; PMCID: PMC6738107.
33
Lin CH, Yap YS, Lee KH, Im SA, Naito Y, Yeo W, Ueno T, Kwong A, Li H, Huang SM, Leung R, Han W, Tan B, Hu FC, Huang CS, Cheng AL, Lu YS; Asian Breast Cancer Cooperative Group. Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population. J Natl Cancer Inst. 2019 Dec 1;111(12):1298-1306. doi: 10.1093/jnci/djz090. PMID: 31093668; PMCID: PMC6910158.
34
Lu LC, Hsu C, Shao YY, Chao Y, Yen CJ, Shih IL, Hung YP, Chang CJ, Shen YC, Guo JC, Liu TH, Hsu CH, Cheng AL. Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Liver Cancer. 2019 Nov;8(6):480-490. doi: 10.1159/000501275. Epub 2019 Aug 6. PMID: 31799205; PMCID: PMC6883443.
35
Shao YY, Liu TH, Hsu C, Lu LC, Shen YC, Lin ZZ, Cheng AL, Hsu CH. Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. Liver Int. 2019 Nov;39(11):2184-2189. doi: 10.1111/liv.14210. Epub 2019 Aug 31. PMID: 31400295.
36
Lin ZZ, Hsu C, Jeng YM, Hu FC, Pan HW, Wu YM, Hsu HC, Hu MC, Cheng AL. Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma. Liver Int. 2019 Sep;39(9):1682-1691. doi: 10.1111/liv.14055. Epub 2019 Jul 11. Erratum in: Liver Int. 2020 Sep;40(9):2309. Hu, Mickey C-T [added]. PMID: 30698907.
37
Shao YY, Li YS, Hsu HW, Lin H, Wang HY, Wo RR, Cheng AL, Hsu CH. Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma. Cancers (Basel). 2019 Sep 26;11(10):1433. doi: 10.3390/cancers11101433. PMID: 31561409; PMCID: PMC6827105.
38
Huang TC, Lin CC, Wu YC, Chia-Hsien Cheng J, Lee JM, Wang HP, Huang PM, Hsu FM, Yeh KH, Cheng AL, Tzen KY, Hsu CH. Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma. J Formos Med Assoc. 2019 Jun;118(6):1024-1030. doi: 10.1016/j.jfma.2018.11.003. Epub 2018 Nov 28. PMID: 30502100.
39
Evans TRJ, Kudo M, Finn RS, Han KH, Cheng AL, Ikeda M, Kraljevic S, Ren M, Dutcus CE, Piscaglia F, Sung MW. Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. Br J Cancer. 2019 Jul;121(3):218-221. doi: 10.1038/s41416-019-0506-6. Epub 2019 Jun 28. Erratum in: Br J Cancer. 2019 Jul 30;: PMID: 31249394; PMCID: PMC6738107.
40
Price T, Shen L, Ma B, Esser R, Chen W, Gibbs P, Lim R, Cheng AL. Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer. Asia Pac J Clin Oncol. 2019 Aug;15(4):225-230. doi: 10.1111/ajco.13154. Epub 2019 May 15. PMID: 31090260; PMCID: PMC6852115.
